Nontraditional Alcohol and Opioid Agonist Treatment Interventions

Overview

Journal Med Clin North Am

Specialty General Medicine

Date 2018 Jun 24

PMID 29933823

Citations 6

Authors

Christopher Fairgrieve

Nadia Fairbairn

Jeffrey H Samet

Seonaid Nolan

Affiliations

Soon will be listed here.

Abstract

Despite the availability of effective medications and psychosocial interventions for the management of a substance use disorder, some individuals repeatedly fail the most aggressive treatment regimens. For such individuals, alternative treatment options exist seeking to mitigate the negative consequences of the use of harmful substances. Participation in a managed alcohol program, or the use of sustained-release oral morphine or injectable opioid agonist treatment or the creation of safe injecting facilities, are examples of such nonstandard approaches. This article reviews the available evidence of these treatment modalities.

Citing Articles

Environmental Uncertainty and Substance Use Disorders: A Behavior Analytic Perspective.

Doyle W, Huskinson S Policy Insights Behav Brain Sci. 2024; 10(1):96-103.

PMID: 38550572 PMC: 10978010. DOI: 10.1177/23727322231152451.

Opioid agonist therapy and mortality among First Nations and other residents with concurrent alcohol use disorder in British Columbia, Canada: A population-based cohort study.

Barker B, Min J, Homayra F, Piske M, Sabeti S, Meilleur L Drug Alcohol Depend. 2023; 250:110908.

PMID: 37544037 PMC: 10895919. DOI: 10.1016/j.drugalcdep.2023.110908.

Choice between food and cocaine or fentanyl reinforcers under fixed and variable schedules in female and male rhesus monkeys.

Doyle W, Freeman K, Woods J, Huskinson S Psychopharmacology (Berl). 2023; 240(7):1573-1585.

PMID: 37266685 PMC: 10581032. DOI: 10.1007/s00213-023-06391-x.

Exploring the experience of inpatients with severe alcohol use disorder on a managed alcohol program (MAP) at St. Paul's Hospital.

Parappilly B, Garrod E, Longoz R, Eligh E, van Heukelom H, Fairgrieve C Harm Reduct J. 2020; 17(1):28.

PMID: 32398062 PMC: 7216705. DOI: 10.1186/s12954-020-00371-6.

Stimulant safe supply: a potential opportunity to respond to the overdose epidemic.

Fleming T, Barker A, Ivsins A, Vakharia S, McNeil R Harm Reduct J. 2020; 17(1):6.

PMID: 31924209 PMC: 6954588. DOI: 10.1186/s12954-019-0351-1.

References

Fichter M, Quadflieg N . Alcoholism in homeless men in the mid-nineties: results from the Bavarian Public Health Study on homelessness. Eur Arch Psychiatry Clin Neurosci. 1999; 249(1):34-44. DOI: 10.1007/s004060050063. View

Babidge N, Buhrich N, Butler T . Mortality among homeless people with schizophrenia in Sydney, Australia: a 10-year follow-up. Acta Psychiatr Scand. 2001; 103(2):105-10. DOI: 10.1034/j.1600-0447.2001.00192.x. View

Rehm J, Gschwend P, Steffen T, Gutzwiller F, Uchtenhagen A . Feasibility, safety, and efficacy of injectable heroin prescription for refractory opioid addicts: a follow-up study. Lancet. 2001; 358(9291):1417-23. DOI: 10.1016/S0140-6736(01)06529-1. View

Wilton P . Shelter "goes wet," opens infirmary to cater to Toronto's homeless. CMAJ. 2003; 168(7):888. PMC: 152010. View

van den Brink W, Hendriks V, Blanken P, Koeter M, van Zwieten B, van Ree J . Medical prescription of heroin to treatment resistant heroin addicts: two randomised controlled trials. BMJ. 2003; 327(7410):310. PMC: 169643. DOI: 10.1136/bmj.327.7410.310. View

Wood E, Kerr T, Small W, Li K, Marsh D, Montaner J . Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. CMAJ. 2004; 171(7):731-4. PMC: 517857. DOI: 10.1503/cmaj.1040774. View

Kerr T, Tyndall M, Li K, Montaner J, Wood E . Safer injection facility use and syringe sharing in injection drug users. Lancet. 2005; 366(9482):316-8. DOI: 10.1016/S0140-6736(05)66475-6. View

Podymow T, Turnbull J, Coyle D, Yetisir E, Wells G . Shelter-based managed alcohol administration to chronically homeless people addicted to alcohol. CMAJ. 2006; 174(1):45-9. PMC: 1319345. DOI: 10.1503/cmaj.1041350. View

Metrebian N, Carnwath Z, Mott J, Carnwath T, Stimson G, Sell L . Patients receiving a prescription for diamorphine (heroin) in the United Kingdom. Drug Alcohol Rev. 2006; 25(2):115-21. DOI: 10.1080/09595230500537175. View

10.

Wood E, Tyndall M, Lai C, Montaner J, Kerr T . Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. Subst Abuse Treat Prev Policy. 2006; 1:13. PMC: 1471778. DOI: 10.1186/1747-597X-1-13. View

11.

Wood E, Tyndall M, Zhang R, Stoltz J, Lai C, Montaner J . Attendance at supervised injecting facilities and use of detoxification services. N Engl J Med. 2006; 354(23):2512-4. DOI: 10.1056/NEJMc052939. View

12.

Stoltz J, Wood E, Small W, Li K, Tyndall M, Montaner J . Changes in injecting practices associated with the use of a medically supervised safer injection facility. J Public Health (Oxf). 2007; 29(1):35-9. DOI: 10.1093/pubmed/fdl090. View

13.

Fischer B, Oviedo-Joekes E, Blanken P, Haasen C, Rehm J, Schechter M . Heroin-assisted treatment (HAT) a decade later: a brief update on science and politics. J Urban Health. 2007; 84(4):552-62. PMC: 2219559. DOI: 10.1007/s11524-007-9198-y. View

14.

Wood R, Wood E, Lai C, Tyndall M, Montaner J, Kerr T . Nurse-delivered safer injection education among a cohort of injection drug users: evidence from the evaluation of Vancouver's supervised injection facility. Int J Drug Policy. 2008; 19(3):183-8. DOI: 10.1016/j.drugpo.2008.01.003. View

15.

Fast D, Small W, Wood E, Kerr T . The perspectives of injection drug users regarding safer injecting education delivered through a supervised injecting facility. Harm Reduct J. 2008; 5:32. PMC: 2605439. DOI: 10.1186/1477-7517-5-32. View

16.

Bayoumi A, Zaric G . The cost-effectiveness of Vancouver's supervised injection facility. CMAJ. 2008; 179(11):1143-51. PMC: 2582765. DOI: 10.1503/cmaj.080808. View

17.

Kastelic A, Dubajic G, Strbad E . Slow-release oral morphine for maintenance treatment of opioid addicts intolerant to methadone or with inadequate withdrawal suppression. Addiction. 2008; 103(11):1837-46. DOI: 10.1111/j.1360-0443.2008.02334.x. View

18.

Andresen M, Boyd N . A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility. Int J Drug Policy. 2009; 21(1):70-6. DOI: 10.1016/j.drugpo.2009.03.004. View

19.

Oviedo-Joekes E, Brissette S, Marsh D, Lauzon P, Guh D, Anis A . Diacetylmorphine versus methadone for the treatment of opioid addiction. N Engl J Med. 2009; 361(8):777-86. PMC: 5127701. DOI: 10.1056/NEJMoa0810635. View

20.

Pinkerton S . Is Vancouver Canada's supervised injection facility cost-saving?. Addiction. 2010; 105(8):1429-36. DOI: 10.1111/j.1360-0443.2010.02977.x. View